Skip to content
DataLookout
Menu

DISPATCHNCT07936799

DISPATCH: Decreasing Intervention Using sFlt-1/PlGF Applied to Chronic Hypertension

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Recruitment rate
Timeframe: At month 6
Protocol adherence in the reveal arm
Timeframe: At month 6

Secondary (15)

Time until delivery using a time-to-event analysis
Delivery with superimposed preeclampsia with severe features.
Rate of preterm birth at <35 weeks
Rate of preterm birth at <37 weeks
Maternal admission rate
Show 10 moreShow less
Maternal admission days
Maternal admission to the ICU
Severe maternal morbidity (with and without transfusion)
Gestational age at delivery
Birthweight
Birthweight percentile
Mode of delivery
Neonatal admission to the NICU
Days of neonatal admission to the NICU
Neonatal composite morbidity

Arms and interventions

Conceal armPlacebo comparator

The clinical team will be blinded to assay results and will manage as per their usual clinical protocol.

Reveal armExperimental

The clinical team will receive qualitative assay results normal (sFlt-1/PlGF \<40) or abnormal (sFlt-1/PlGF ³40)) and the ratio value and concentrations of PlGF and sFlt-1.

Diagnostic tests: sFlt/PlGF lab assay with change in clinical care, sFlt/PlGF without change in clinical care

Sites

1 site in 1 country

  • University of California, San FranciscoSan Francisco, California, United States